Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Bicyclic compound and use thereof for medical purposes

A compound and drug technology, applied in the field of bicyclic compounds and their medical applications, can solve the problems of low stimulant effect, no record or teaching, etc., and achieve a strong effect of lowering intraocular pressure

Active Publication Date: 2014-04-02
ONO PHARMA CO LTD
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0051] The compounds of the present invention have low agonistic effects on IP receptors and EP1 receptors and have selective agonistic effects on FP receptors, but no such feature (selectivity) is described or taught in any prior art

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Bicyclic compound and use thereof for medical purposes
  • Bicyclic compound and use thereof for medical purposes
  • Bicyclic compound and use thereof for medical purposes

Examples

Experimental program
Comparison scheme
Effect test

preparation example Construction

[0188] [Preparation method of the compound of the present invention]

[0189] The compounds of the invention can be prepared by known methods, for example by Comprehensive Organic Transformations: A Guide to Functional Group Preparations 2 nd Edition (Richard C. Larock, John Wiley & Sons Inc, 1999), or can be prepared by appropriately modifying the methods disclosed in the examples and using in combination.

[0190] Among the compounds represented by the general formula (I), for the compounds represented by the general formula (I-2),

[0191] [chemical formula 26]

[0192]

[0193] As shown below, the α chain represents the β configuration, and the R 1 on behalf of COOR 2 , R 5 represents a hydroxyl group, and R 6 and R 7 One represents hydrogen, the other represents hydroxyl,

[0194] That is the compound shown in general formula (I-2-a):

[0195] [chemical formula 27]

[0196]

[0197] (wherein all symbols represent the same meaning as above)

[0198] Can us...

Embodiment 1

[0295] Example 1: (3aR, 4S, 5R, 6aS)-4-({[dimethyl(2-methyl-2-propyl)silyl]oxy}methyl)-5-(tetrahydro- 2H-pyran-2-yloxy)hexahydro-2H-cyclopenta[b]furan-2-one

[0296] Under ice cooling, to (3aR, 4S, 5R, 6aS)-4-(hydroxymethyl)-5-(tetrahydro-2H-pyran-2-yloxy)hexahydro-2H-cyclopentadiene [b] Imidazole (29.22g) and tert-butyldimethylsilyl chloride (30.87g) were successively added to a solution of furan-2-one (50g) in dimethylformamide (hereinafter sometimes abbreviated as DMF) (100mL) , and the mixture was stirred at room temperature for 3.5 hours. After the reaction was completed, a small amount of ethanol was added, the reaction solution was poured into ice water, and extracted with ethyl acetate:hexane (2:3). The extract was washed with 1N hydrochloric acid, saturated aqueous sodium bicarbonate, and saturated brine, dried over sodium sulfate, and concentrated under reduced pressure to obtain the title compound (76.2 g) having the following physical properties:

[0297] TLC: R...

Embodiment 2

[0298] Example 2: (3aR, 4S, 5R, 6aS)-4-({[dimethyl(2-methyl-2-propyl)silyl]oxy}methyl)-5-(tetrahydro- 2H-pyran-2-yloxy)hexahydro-2H-cyclopenta[b]furan-2-ol

[0299] Under an argon atmosphere, the anhydrous toluene (390 mL) solution of the compound (76.2 g) prepared in Example 1 was cooled to -70° C., and a toluene solution of 1 mol / L diisobutylaluminum hydride ( 212.4 mL), which was then stirred for 30 minutes. After completion of the reaction, the reaction solution was diluted with tert-butyl methyl ether (hereinafter sometimes abbreviated as MTBE) (400 mL), and a saturated aqueous sodium sulfate solution was added. The precipitated white precipitate was filtered using Celite (trade name), and the solvent was concentrated under reduced pressure to obtain the title compound (80.7 g) having the following physical properties:

[0300] TLC: Rf 0.30 (hexane:ethyl acetate=3:1).

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

Since a compound represented by the general formula (I) (wherein definition of each group is as described in the specification), a salt thereof, a solvate thereof, or a prodrug thereof has strong and sustaining intraocular pressure lowering activity and, further, has no side effect on eyes such as ocular stimulating property (hyperemia, corneal clouding etc.), aqueous humor protein rise etc., it has high safety, and can be an excellent agent for preventing and / or treating glaucoma etc.

Description

technical field [0001] The present invention relates to a compound represented by general formula (I), a salt thereof, a solvate thereof or a prodrug thereof (hereinafter, abbreviated as the compound of the present invention in some cases), [0002] [chemical formula 1] [0003] [0004] All the symbols therein represent the same meanings as described below. Background technique [0005] Glaucoma is an eye disease characterized by functional impairment of vision, resulting in temporary or permanent visual field loss and vision loss. This is due to the accumulation of aqueous humor caused by the circulation disorder of aqueous humor, and the continuous increase of intraocular pressure causes compression of optic nerve. Lowering intraocular pressure is effective for glaucoma treatment, and in order to lower intraocular pressure, treatments such as drug therapy (eye drops, internal therapy, infusion therapy), laser therapy, or surgical therapy are performed. [0006] Conv...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Patents(China)
IPC IPC(8): C07D313/06A61K31/4427A61K31/558A61P27/02A61P27/06A61P27/10A61P27/12A61P43/00C07D401/06C07D417/04
CPCA61K31/558C07D407/12C07D401/06C07D313/06C07D417/04A61K31/4427C07D405/06A61K31/335A61P27/00A61P27/02A61P27/06A61P27/10A61P27/12A61P43/00Y10S623/905A61K9/0048
Inventor 神户透丸山透山根晋作中山仁志谷耕辅
Owner ONO PHARMA CO LTD
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com